[Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease].

IF 1.1 4区医学 Q4 CLINICAL NEUROLOGY

Nervenarzt Pub Date : 2025-06-23 DOI:10.1007/s00115-025-01839-1

Daniel J Müller, Christine M Freitag, Urs Heilbronner, Markus M Nöthen, Robert Perneczky, Marcella Rietschel, Eva C Schulte, Jürgen Deckert

引用次数: 0

Abstract

The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.

查看原文本刊更多论文

[精神病学的遗传知情治疗：通过APOE和抗体治疗阿尔茨海默病的新动态]。

欧洲药品管理局建议在用Lecanemab治疗阿尔茨海默病之前检测apoe基因型。该药物的批准仅限于ApoE ε 4等位基因不纯合的患者。这是为了减少用来卡耐单抗治疗的患者发生不良反应的风险。有了这一建议，精神病学治疗将首次被告知基因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nervenarzt 医学-精神病学

CiteScore

2.50

自引率

18.20%

发文量

169

审稿时长

4-8 weeks

期刊介绍： Der Nervenarzt is an internationally recognized journal addressing neurologists and psychiatrists working in clinical or practical environments. Essential findings and current information from neurology, psychiatry as well as neuropathology, neurosurgery up to psychotherapy are presented. Review articles provide an overview on selected topics and offer the reader a summary of current findings from all fields of neurology and psychiatry. Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.